BiogenBIIB
BIIB
About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Employees: 7,605
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
24% more repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 263
22% more first-time investments, than exits
New positions opened: 127 | Existing positions closed: 104
1% more funds holding
Funds holding: 855 [Q4 2024] → 863 (+8) [Q1 2025]
3.41% less ownership
Funds ownership: 90.14% [Q4 2024] → 86.73% (-3.41%) [Q1 2025]
14% less capital invested
Capital invested by funds: $20.1B [Q4 2024] → $17.4B (-$2.72B) [Q1 2025]
44% less call options, than puts
Call options by funds: $345M | Put options by funds: $621M
50% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$115
14%
downside
Avg. target
$179
33%
upside
High target
$255
90%
upside
11 analyst ratings
7 positive
64%
4 neutral
36%
0 negative
0%
RBC Capital Brian Abrahams | 59%upside $213 | Outperform Reiterated | 27 Jun 2025 |
HC Wainwright & Co. Andrew Fein | 39%upside $187 | Buy Reiterated | 26 Jun 2025 |
Piper Sandler David Amsellem | 14%downside $115 | Neutral Reiterated | 12 Jun 2025 |
Wedbush Laura Chico | 10%downside $121 | Neutral Reiterated | 12 Jun 2025 |
Mizuho Salim Syed | 26%upside $169 | Outperform Maintained | 7 May 2025 |
Financial journalist opinion
Based on 11 articles about BIIB published over the past 30 days
Neutral
Business Wire
1 day ago
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a.
Neutral
GlobeNewsWire
1 day ago
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass.
Negative
Zacks Investment Research
1 week ago
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
Neutral
GlobeNewsWire
1 week ago
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.
Neutral
GlobeNewsWire
2 weeks ago
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen's applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.
Positive
Investors Business Daily
2 weeks ago
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.
Neutral
GlobeNewsWire
2 weeks ago
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once yearly dosing. An interim analysis of the Phase 1 study in participants with SMA who were previously treated with gene therapy was conducted to inform the decision on whether to move salanersen forward into registrational studies. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data shows clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over 1 year. These data will be presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.
Positive
Seeking Alpha
2 weeks ago
Biogen: Investors Are Missing The Bigger Picture
Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter of 2025. So, the strong demand for Skyclarys and Leqembi helps strengthen Biogen's balance sheet and also allows it to actively rejuvenate its portfolio of product candidates aimed at treating autoimmune diseases.
Positive
Market Watch
3 weeks ago
20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks
These companies have reduced their share counts the most over the past 10 years
Neutral
GlobeNewsWire
3 weeks ago
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to
Charts implemented using Lightweight Charts™